Current Status of Imaging Diagnosis and Treatment of Subcentimeter Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Current Status of Imaging Diagnosis and Treatment of Subcentimeter Hepatocellular Carcinoma

Published:2023-12 Issue:6 Volume:3 Page:408-419
ISSN:2210-2981
Container-title:Current Chinese Science
language:en
Short-container-title:CCS

Author:

Huang Peng¹²,Xiao Yuyao¹³,Zhou Changwu⁴³⁵,Wu Fei¹³,Yang Chun¹³,Zeng Mengsu¹³⁵

Affiliation:

1. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China

2. Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China

3. Department of Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China

4. Department of Radiology, Zhongshan Hospital, c, Shanghai, China

5. Department of Radiology, Shanghai Institute of Medical Imaging, Shanghai, China

Abstract

Abstract: Significant advances in liver imaging technology have facilitated the early detection of subcentimeter hepatocellular carcinoma (HCC). Contrast-enhanced ultrasound, computed tomography, and magnetic resonance imaging (MRI) can be used to diagnose subcentimeter HCC based on the typical imaging features of HCC. Ancillary imaging features such as T2 weightedimaging mild-moderate hyperintensity, restricted diffusion, and hepatobiliary phase hypointensity may improve the diagnostic accuracy of gadoxetic acid-enhanced MRI for subcentimeter HCC. More information is needed to choose between immediate treatment or watchful waiting in subcentimeter HCC. Surgical resection, ablation, and transarterial chemoembolization are effective and safe methods for the management of subcentimeter HCC.

Funder

Clinical Research Plan of SHDC

National Natural Science Foundation of China

Shanghai Municipal Key Clinical Specialty

Clinical Research Project of Zhongshan Hospital, Fudan University

Publisher

Bentham Science Publishers Ltd.

Subject

General Medicine

Reference85 articles.

1. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249

2. Zhou J.; Sun H.C.; Wang Z.; Cong W.M.; Wang J.H.; Zeng M.S.; Yang J.M.; Bie P.; Liu L.X.; Wen T.F.; Han G.H.; Wang M.Q.; Liu R.B.; Lu L.G.; Ren Z.G.; Chen M.S.; Zeng Z.C.; Liang P.; Liang C.H.; Chen M.; Yan F.H.; Wang W.P.; Ji Y.; Cheng W.W.; Dai C.L.; Jia W.D.; Li Y.M.; Li Y.X.; Liang J.; Liu T.S.; Lv G.Y.; Mao Y.L.; Ren W.X.; Shi H.C.; Wang W.T.; Wang X.Y.; Xing B.C.; Xu J.M.; Yang J.Y.; Yang Y.F.; Ye S.L.; Yin Z.Y.; Zhang B.H.; Zhang S.J.; Zhou W.P.; Zhu J.Y.; Liu R.; Shi Y.H.; Xiao Y.S.; Dai Z.; Teng G.J.; Cai J.Q.; Wang W.L.; Dong J.H.; Li Q.; Shen F.; Qin S.K.; Fan J.; Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer 2018,7(3),235-260

3. Reig M.; Forner A.; Rimola J.; Ferrer-Fàbrega J.; Burrel M.; Garcia-Criado Á.; Kelley R.K.; Galle P.R.; Mazzaferro V.; Salem R.; Sangro B.; Singal A.G.; Vogel A.; Fuster J.; Ayuso C.; Bruix J.; BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022,76(3),681-693

4. Kudo M.; Kawamura Y.; Hasegawa K.; Tateishi R.; Kariyama K.; Shiina S.; Toyoda H.; Imai Y.; Hiraoka A.; Ikeda M.; Izumi N.; Moriguchi M.; Ogasawara S.; Minami Y.; Ueshima K.; Murakami T.; Miyayama S.; Nakashima O.; Yano H.; Sakamoto M.; Hatano E.; Shimada M.; Kokudo N.; Mochida S.; Takehara T.; Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 2021,10(3),181-223

5. Lu X.Y.; Xi T.; Lau W.Y.; Dong H.; Xian Z.H.; Yu H.; Zhu Z.; Shen F.; Wu M.C.; Cong W.M.; Pathobiological features of small hepatocellular carcinoma: Correlation between tumor size and biological behavior. J Cancer Res Clin Oncol 2011,137(4),567-575